Chromocell Return On Equity from 2010 to 2025
| CHRO Stock | USD 1.80 0.38 17.43% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter 1.03 | Current Value 1.08 | Quarterly Volatility 0.3693102 |
Check Chromocell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Chromocell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Expense of 626.1 K or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 111, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Chromocell financial statements analysis is a perfect complement when working with Chromocell Therapeutics Valuation or Volatility modules.
Chromocell | Return On Equity |
Latest Chromocell Therapeutics' Return On Equity Growth Pattern
Below is the plot of the Return On Equity of Chromocell Therapeutics over the last few years. Return on Equity is the amount of Chromocell Therapeutics net income returned as a percentage of Chromocell Therapeutics equity. Return on equity measures Chromocell Therapeutics profitability by revealing how much profit Chromocell Therapeutics generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Chromocell Therapeutics' Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Chromocell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.0 | 10 Years Trend |
|
Return On Equity |
| Timeline |
Chromocell Return On Equity Regression Statistics
| Arithmetic Mean | 0.38 | |
| Geometric Mean | 0.28 | |
| Coefficient Of Variation | 96.69 | |
| Mean Deviation | 0.30 | |
| Median | 0.18 | |
| Standard Deviation | 0.37 | |
| Sample Variance | 0.14 | |
| Range | 0.9835 | |
| R-Value | 0.74 | |
| Mean Square Error | 0.07 | |
| R-Squared | 0.55 | |
| Significance | 0.001 | |
| Slope | 0.06 | |
| Total Sum of Squares | 2.05 |
Chromocell Return On Equity History
About Chromocell Therapeutics Financial Statements
Chromocell Therapeutics investors utilize fundamental indicators, such as Return On Equity, to predict how Chromocell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Return On Equity | 1.03 | 1.08 |
Pair Trading with Chromocell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chromocell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chromocell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Chromocell Stock
Moving against Chromocell Stock
| 0.81 | ZURA | Zura Bio Limited | PairCorr |
| 0.77 | MLTX | MoonLake Immunotherapeuti | PairCorr |
| 0.76 | PEPG | PepGen | PairCorr |
| 0.75 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.74 | MLYS | Mineralys Therapeutics, Trending | PairCorr |
The ability to find closely correlated positions to Chromocell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Chromocell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Chromocell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Chromocell Therapeutics to buy it.
The correlation of Chromocell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Chromocell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Chromocell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Chromocell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Chromocell Therapeutics Correlation against competitors. To learn how to invest in Chromocell Stock, please use our How to Invest in Chromocell Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chromocell Therapeutics. If investors know Chromocell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chromocell Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chromocell Therapeutics is measured differently than its book value, which is the value of Chromocell that is recorded on the company's balance sheet. Investors also form their own opinion of Chromocell Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chromocell Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chromocell Therapeutics' market value can be influenced by many factors that don't directly affect Chromocell Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chromocell Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chromocell Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chromocell Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.